Total Funding
32
46
Total FundingSeed raised
Growth Score
-2 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
147237
Nova Satra Dx is a molecular diagnostics company.
Shane Glynn: Director of Finance & AdministrationPast Role: James Cook University, Lecturer - Finance
About the Company
Nova Satra Dx is a molecular diagnostics company headquartered in Singapore. The company is committed to empowering patients and physicians through the research, development and commercialisation of novel blood based diagnostic tests.
These tests provide rapid and accurate detection of cancer using Asian-specific epigenetic biomarkers. Based on
its clinically validated NovoTect™ technology developed by the University of Oxford, Nova Satra’s diagnostic tests can detect and identify changes in gene expression which are linked to cancer.
The company is developing a pipeline of tests for breast, colon, prostate, stomach and lung cancers. For more information, please visit www.novasatra.com
